UroGen

9 Ha’Ta’asiya Street
Ra’anana
4365007

Tel: 972-9-7707600

Show jobs for this employer

About UroGen

UroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC. In addition, UroGen is developing an additional clinical-stage drug candidate, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer. The company has recently licensed BotuGel for the treatment of overactive bladder and interstitial cystitis, to Allergan for further development.
YEAR FOUNDED:
2005
LEADERSHIP:
CEO: Ron Bentsur
CFO: Gary Titus
CLINICAL TRIAL:
Please click here for clinical trial information.

36 articles with UroGen